UPDATE: JPMorgan Double Downgrades Sarepta Therapeutics (SRPT) to Underweight
Tweet Send to a Friend
(Updated - January 8, 2021 5:58 AM EST)
JPMorgan analyst Anupam Rama downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Anupam Rama downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
